.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Primary Tube Versus Trabeculectomy (PTVT) Study provides long-term comparative evidence for two established glaucoma operations. At five years, mean intraocular pressure was very similar after Baerveldt tube shunt surgery and trabeculectomy with mitomycin C. The cumulative probability of failure also did not differ significantly between the treatment groups. One clinically relevant difference was medication burden: patients in the trabeculectomy group required fewer glaucoma medications at five years. The findings are useful when counseling patients with medically uncontrolled glaucoma because they show that both procedures can achieve substantial and durable pressure lowering, but their postoperative profiles differ. Tube shunts may be attractive in eyes where prior surgery or conjunctival considerations influence the choice, while trabeculectomy can achieve excellent pressure control with a lower medication burden in appropriately selected eyes. The study reinforces that glaucoma surgery decisions should be individualized rather than framed around one universally superior procedure. Surgeon experience, target IOP, conjunctival status, prior operations, scarring risk, and the patient's tolerance for postoperative follow-up all remain important determinants of the final surgical strategy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The Primary Tube Versus Trabeculectomy (PTVT) Study provides long-term comparative evidence for two established glaucoma operations. At five years, mean intraocular pressure was very similar after Baerveldt tube shunt surgery and trabeculectomy with mitomycin C. The cumulative probability of failure also did not differ significantly between the treatment groups. One clinically relevant difference was medication burden: patients in the trabeculectomy group required fewer glaucoma medications at five years. The findings are useful when counseling patients with medically uncontrolled glaucoma because they show that both procedures can achieve substantial and durable pressure lowering, but their postoperative profiles differ. Tube shunts may be attractive in eyes where prior surgery or conjunctival considerations influence the choice, while trabeculectomy can achieve excellent pressure control with a lower medication burden in appropriately selected eyes. The study reinforces that glaucoma surgery decisions should be individualized rather than framed around one universally superior procedure. Surgeon experience, target IOP, conjunctival status, prior operations, scarring risk, and the patient's tolerance for postoperative follow-up all remain important determinants of the final surgical strategy.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
